Algernon CEO and CSO to Discuss New DMT Stroke Clinical Research Program Featured on BioPub Webcast Hosted by Dr. KSS MD, PhD
Algernon CEO and CSO to Discuss New DMT Stroke Clinical Research Program Featured on BioPub Webcast Hosted by Dr. KSS MD, PhD Algernon Pharmaceuticals Inc. a clinical stage pharmaceutical development company, is pleased to announce that Algernon’s CEO Christopher J. Moreau and CSO Dr. Mark Williams, will be discussing the Company’s New DMT Stroke Clinical Research Program on an upcoming BioPub webcast. The webcast will be held Wednesday February 3, 2021 hosted by Dr. KSS at Noon EST. The Company invites interested shareholders, … Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: A...
Source: investingnews.com